stable on clozapine. Between examinations there will be no planned interference with the antipsychotic treatment, but antipsychotic treatment may be changed during the period in the intention to improve symptoms. The primary longitudinal outcome is comparing changes in BBB-permeability along with symptom-fluctuations. This will be done by comparing changes in qAbL, which is the gold standard technique measuring the CSF:serum albumin ratio (QAbL).

Results: The study has been approved by the regional ethical committee and data collection will begin in 2020.

Discussion: We expect the obtained results will contribute to a better pathophysiological understanding about illness markers and their progression over time and in relation to functional outcome.

T11. CORONARY ARTERY CALCIFICATION IN PEOPLE WITH SCHIZOPHRENIA

Trine Trab*,1, René Ernst Nielsen1, Jens Broendum Froekjaer1, Svend Eggert Jensen1
1 Aalborg University Hospital

Background: Coronary artery disease (CAD) is one of the major causes of premature mortality in patients with schizophrenia. Coronary artery calcification (CAC) is an independent predictor of cardiac mortality and CAD in the general population, but has not yet been investigated in patients with schizophrenia. The aim of the present study is to compare CAC quantified by cardiac computed tomography (CT) in patients with schizophrenia to the general population.

Methods: Baseline data from an ongoing prospective cohort study including 200 patients with schizophrenia (ICD-10 diagnoses F20 or F25) diagnosed at least 10 years prior to inclusion (chronic group) and 86 patients with schizophrenia diagnosed within two years prior to inclusion (debut group). Patients in the debut group were matched 1:1 on age, gender and smoking status with psychiatrically healthy controls (PHC). All participants underwent cardiac CT and the CAC was quantified using Agatston Score. Mean CAC in the chronic group was compared to reference CAC scores whilst mean CAC in the debut group was compared to PHC. Information on cardiovascular risk factors, illness history, social and psychiatric conditions were obtained at baseline.

Results: Data is currently being analyzed and results will be presented at the Congress of International Schizophrenia Research Society.

Discussion: If the CAC quantified by CT in patients with schizophrenia differs from the PHC population, it might act as a tool for early detection of CAD in these patients. Thus, the findings of this study might contribute to preventive strategies in order to decrease cardiovascular mortality.

T12. THE RELATIONSHIP OF INTESTINAL PERMEABILITY FACTORS WITH SOCIODEMOGRAPHIC AND PHYSICAL HEALTH FACTORS AND PANSS SCORES IN SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROLS

Jenny Borkent*,1, Iris E. C. Sommer1, Bartholomeus C. M. Haarman1
1 University Medical Center Groningen

Background: Recent studies have pointed to the gut-brain axis as a new venue for treatment of psychiatric disorders, with increased inflammation stemming from increased intestinal permeability to further affect brain functioning in a significant subset of patients. Yet, this line of research is still in its infancy, with multiple studies showing increased intestinal permeability in schizophrenia and bipolar disorders, demonstrated as translocation of food and bacterial antigens, as well as intestinal microbiome disturbances.

Methods: Therefore, we measured intestinal permeability markers soluble CD14 (sCD14) and lipopolysaccharide binding protein (LBP) in schizophrenia patients and healthy controls. Intestinal permeability markers were compared to several sociodemographic, including age, gender and BMI, and physical health variables, including CRP, glucose, cholesterol, triglycerides, HDL, LDL and non-HDL, and Positive and Negative Syndrome Scale (PANSS) scores. Of the control group (n = 43), 76.7% was male, with a mean age of 25.1 years. Of the schizophrenia group (n = 105) 75.2% was male, with a mean age of 27.4 years and an average PANSS score of 57.2.

Results: Levels of LBP and sCD14 were not significantly different between schizophrenia patients and controls. LBP and sCD14 levels were neither correlated in the control group, nor in the schizophrenia group. In the control group Females had elevated LBP levels compared to males (p < 0.01), but not in the schizophrenia group. Quantitative levels of LBP, but not sCD14, correlated with triglycerides in the schizophrenia group (R2 = 0.049, p < 0.05). Furthermore, quantitative levels of sCD14, but not LBP, correlated with CRP in the schizophrenia group (R2 = 0.078, p < 0.05). Finally, LBP levels in patients correlated with PANSS negative scores (R2 = 0.055, p < 0.05). Neither a correlation of LBP and sCD14 with age, nor with BMI was observed in both the control and the schizophrenia group.

Discussion: In conclusion, these intestinal permeability markers showed few differences between the schizophrenia and the control group. We found weak, yet significant correlations with triglycerides, CRP and severity of negative symptoms, which may be caused by poor eating habits or metabolic syndrome leading to leaky gut in the more severely affected patients. These results are not in line with results of Severance et al. (2013), who performed a similar analysis and found differences in intestinal permeability markers between a control group and a schizophrenia group. Furthermore, they did observe a positive correlation between sCD14 and LBP in both the control and the schizophrenia group. The difference between that study and our current findings may stem from the different patients samples, as we assessed patients in their first five years after diagnosis, when metabolic syndrome was less abundant.

T13. CORNEAL CONFOCAL MICROSCOPY DETECTS NEURAL CHANGES IN SCHIZOPHRENIA

Peter Woodruff*,1, Georgios Ponirakis*,2, Reem Ghandi1, Amani Hussein1, Anjushri Bhagat1, Ioannis Petropoulos1, Adnan Khan2, Hoda Gad2, Ahmed Aly Al Sotouhy1, Ahmed Own1, Surjith Vattoth1, Marwan Ramadan1, Hanadi Al Hamad4, James Currie1, Rayaz A Malik2
1 Academic Health System- Mental Health, Hamad Medical Corporation; 2 Well Cornell Medical College- Qatar; 3 Neuroscience Institute, Hamad Medical Corporation; 4 Hamad Medical Corporation

Background: A combination of neurodevelopmental and degenerative neural changes are likely to underpin positive and negative symptoms in schizophrenia. However, there are currently no validated biomarkers to accurately quantify the extent of neural changes in schizophrenia. Corneal confocal microscopy (CCM) is a non-invasive ophthalmic imaging technique that has been used to demonstrate in vivo corneal nerve fiber abnormalities in a range of peripheral neuropathies and central neurodegenerative disorders including Parkinson's disease, multiple sclerosis and dementia.

We wished to test the hypothesis that corneal nerve abnormalities occur in patients with schizophrenia, particularly those with negative symptoms and cognitive impairment.

Methods: Patients with DSM-V schizophrenia without other causes of peripheral neuropathy other than metabolic syndrome underwent assessment...
of clinical ratings (Positive and Negative Symptoms Scale (PANSS), cognitive function (Montreal Cognitive Assessment (MOCA)) and Corneal confocal microscopy (CCM), vibration perception threshold (VPT) and sudomotor function testing.

Healthy controls underwent the same assessments apart from PANSS.

Results: 55 subjects without (n=38) and with schizophrenia (n=17) with comparable mean age (35.7±8.5 vs 35.6±12.2, P=0.96) were studied. Patients with schizophrenia had significantly higher body weight (93.9±23.5 vs 77.1±10.1, P=0.02) and lower Low Density Lipoproteins (2.6±1.0 vs 3.4±0.7, P=0.02) compared with healthy controls.

The proportion of gender, systolic and diastolic blood pressure, HbA1c, cholesterol, triglyceride and High Density Lipoproteins were comparable between the two groups.

Patients with schizophrenia had significantly lower corneal nerve fibre density (CNFD, fibers/mm2) (35.6±6.5 vs 33.5±7.8, p<0.0001), branch density (CNBD, branches/mm2) (98.1±30.6 vs 34.4±26.9, p<0.0001), and fibre length (CNFL, mm/mm2) (24.2±3.9 vs 14.3±4.7, p<0.0001) compared with healthy controls but no difference in peripheral neuropathy assessed by VPT and sudomotor function testing.

The area under the Receiver Operating Characteristic Curve (95% CI) of CNFD, CNBD, CNFL to distinguish patients with schizophrenia from healthy controls were 87.0% (76.8–98.2%), 93.2% (84.2–102.3%), 93.2% (84.4–102.1%), respectively.

Discussion: These preliminary results:
1. support the hypothesis that corneal nerve abnormalities occur in schizophrenia;
2. corneal confocal microscopy has high diagnostic capability to distinguish subjects with schizophrenia from healthy controls;
3. provide evidence to support the potential application of corneal confocal microscopy as a non-invasive technique to detect neural change in schizophrenia.

T14. HYPOTHALAMIC-PITUITARY-GONADAL AXIS HORMONES IN ANTIPSYCHOTIC NAÏVE FIRST-EPISODE OF PSYCHOSIS AND HEALTHY CONTROLS

Maria Teresa Pons-Cabrera1, Maria Sagüé-Vilavela1, Alexandre González-Rodríguez2, Santiago Madero3, Mireia Vázquez1, Victòria Soler-Catá1, Emilio Fernández-Egea1, Brian Kirkpatrick4, Javier Labad1, Miquel Bernardo5, Clemente García-Rizo6

1Hospital Clinic, Neuroscience Institute, Barcelona; 2Parc Taulí University Hospital; 3IBPT, Autonomous University of Barcelona (UAB); Sabadell; 4University of Cambridge, Cambridgehire and Peterborough NHS Foundation Trust, Hungtindon, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM); 5University of Nevada School of Medicine; 6Parc Taulí University Hospital; 3IBPT; CIBERSAM; UAB; Sabadell; 4Neuroscience Institute, Hospital Clinic, University of Barcelona, CIBERSAM; Institute of Biomedical Research Agustí Pi i Sunyer (IDIBAPS)

Background: Kraepelin (1909) wrote about the association between female sex hormones and psychotic symptoms. He observed that women diagnosed with schizophrenia showed signs of gonadal dysfunction and hypoestrogenism. Antipsychotic drugs had not yet been introduced, so it cannot be interpreted as side effects. At the beginning of the 20th-century, the rhythmicity of psychotic symptoms through menstrual cycle was observed. The symptoms ameliorated when higher levels of estrogens were found. It was also noted during pregnancy. Reported cases and some studies confirmed these observations. Epidemiology shows a later peak of onset of psychosis in women. This protective role, also observed in clinical and animal studies, remains for the reproductive years and decreases by the time of menopause, when there’s a second important peak of onset in women.

In spite of all these observations, few systematic investigations have been published about the effects of estrogens in women with schizophrenia. This study aims to investigate differences in the levels of sexual hormones between antipsychotic-naive women with and without psychosis.

Methods: We performed a retrospective case-control study to compare the levels of sex hormones in blood of first-episode psychosis (FEP) and healthy control women (HC) of reproductive age, as a part of a NIH-NIDDK project on the study of hormonal factors and metabolism in psychosis. All participants were antipsychotic-naive, in order to avoid bias from antipsychotic medication use. Four cases and four controls were recruited: cases were women newly diagnosed with primary non-affective psychosis at the emergency department of our hospital, and controls were mental health workers of similar age with no history of psychosis. Blood samples were obtained at the luteal phase of the menstrual cycle. We registered the following variables: age, psychosis status, last menstrual day and hormone blood levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol and progesterone. We used descriptive statistics for age and hormone blood levels (mean and standard deviation -SD-) and we performed the Kruskal-Wallis test to determine any statistical differences of these variables regarding psychosis status.

All participants provided informed consent. Ethical approval was obtained from the institutional ethics review board.

Results: The mean age of FEP was 31.4 years (SD 1.9) and 26.1 years (SD 3.5) for HC, with no statistically significant differences. Both FSH and LH were higher in FEP (FSH: mean 7 U/L, SD 1.7; LH: mean 8.4 U/L, SD 2.6) compared to HC (FSH: mean 3.5 U/L, SD 1.2; LH: mean 5.7 U/L, SD 3.3), reaching statistical significance in the case of FSH (p=0.015). 17β-estradiol was lower in FEP (mean 75.3 pg/mL, SD 54.6) than in HC (mean 151 ng/mL, SD 102.1), although differences were not statistically significant.

Discussion: We observed higher levels of FSH in women with psychosis compared to controls in the luteal phase. These women were antipsychotic-naïve; thus, these results are not a consequence of medication use. Our observations add evidence to the known relationship between altered hormonal levels and schizophrenia in women. The increase in FSH stimulates the production of estrogens, which are known to be low in psychosis compared to healthy controls. This finding supports the hypoestrogenism hypothesis of schizophrenia.

Future studies with larger samples evaluating hormonal levels, psychotic symptoms and differences with hormonal treatments could lead to research of new adjunctive therapies or approaches.

T15. MISMATCH NEGATIVITY INDICES AS A PROGNOSTIC FACTOR FOR REMISSION IN SCHIZOPHRENIA

Se-Hoon Shim1, Eunsung Lim2, Sung-Yong Park3, Seung-Ho Jang4, Won-Myong Bahk5, Young-Joon Kwon1, Bo-Hyun Yoon6

1Soochunhyang University Cheonan Hospital; 2Shinseog Hospital, Kimje; 3Keyo Hospital, Uijeong; 4Wonkwang University Hospital; 5Yeouido St. Mary’s Hospital, The Catholic University of Korea, Seoul; 6Naju National Hospital

Background: Mismatch negativity (MMN) is an event-related potential component when a sequence of relatively standard stimuli is interrupted by the infrequent presentation of deviant stimuli. MMN is known to be associated with neuro-cognition and functional outcomes. Also, abnormally decreased MMN has often been reported in schizophrenia. Remission and recovery rates are related to the neuro-cognition of patients with schizophrenia. The present study explored the relationship of MMN with remission in patients with schizophrenia.

Methods: Forty patients with schizophrenia were recruited and divided into two groups, with or without remission, according to the Remission